Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures

The outbreak of a novel febrile respiratory disease called COVID-19, caused by a newfound coronavirus SARS-CoV-2, has brought a worldwide attention. Prioritizing approved drugs is critical for quick clinical trials against COVID-19. In this study, we first manually curated three Virus-Drug Associati...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Lihong, Shen, Ling, Xu, Junlin, Tian, Xiongfei, Liu, Fuxing, Wang, Juanjuan, Tian, Geng, Yang, Jialiang, Zhou, Liqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973547/
https://www.ncbi.nlm.nih.gov/pubmed/33737523
http://dx.doi.org/10.1038/s41598-021-83737-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973547/
https://www.ncbi.nlm.nih.gov/pubmed/33737523
http://dx.doi.org/10.1038/s41598-021-83737-5

Ejemplares similares